<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04768400</url>
  </required_header>
  <id_info>
    <org_study_id>3-2020-0511</org_study_id>
    <nct_id>NCT04768400</nct_id>
  </id_info>
  <brief_title>MEP and Neuromuscular Blocker</brief_title>
  <official_title>Quantitative Analysis Between Neuromuscular Blocking Agent and Motor Evoked Potential and Analysis of Risk Factors for the Coefficient of Variance of Motor Evoked Potential in Patients Undergoing Brain Tumor Removal Surgery: Population Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is important to predict the influence of the neuromuscular blocking agents on the motor&#xD;
      evoked potential. Investigator will investigate the dose-response relationship between the&#xD;
      degree of the neuromuscular blockade and the motor evoked potential in patients undergoing&#xD;
      brain tumor surgery using the population approach. Investigator will investigate the&#xD;
      influence of the other factors such as the impedence, reactance, muscel amount, and age on&#xD;
      the motor evoked potential.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amplitude of the motor evoked potential</measure>
    <time_frame>At intraoperative 0 hr from the start of the anesthetic induction</time_frame>
    <description>Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the start of the anesthetic induction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amplitude of the motor evoked potential</measure>
    <time_frame>At intraoperative 0 h from the opening of the dura</time_frame>
    <description>Amplitude of the motor evoked potential will be evaluated at intraoperative 0 h from the opening of the dura.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>rocuronium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neuromuscular blockade will be performed using rocuronium.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arm I (MEP)</intervention_name>
    <description>Arm I (MEP): Motor evoked potential will be measured in various degree of the neuromuscular blockade.</description>
    <arm_group_label>rocuronium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Patients aged 19 years old or older, with American Society of Anesthesiologists Physical&#xD;
        Status 1-3, and scheduled for elective brain tumor surgery under the monitoring of the&#xD;
        motor evoked potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Central or peripheral neuromuscular disease&#xD;
&#xD;
          2. Sensory or motor nerve disorder&#xD;
&#xD;
          3. Allergy to propofol, remifentanil, and rocuronium&#xD;
&#xD;
          4. Patients with pacemaker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dong woo Han</last_name>
    <phone>82-2-2224-3919</phone>
    <email>hanesth@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DongWoo DongWoo</last_name>
      <phone>82-2-2019-4601</phone>
      <email>gsirb@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>DongWoo DongWoo</last_name>
      <phone>82-2-2019-</phone>
      <phone_ext>2740</phone_ext>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Dong Woo Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

